Interplay of bromodomain and histone acetylation in the regulation of p300-dependent genes

References

• Arany Z, Newsome D, Oldread E, Livingston DM, Eckner R. A family of transcriptional adaptor proteins targeted by the E1A oncoprotein. Nature 1995; 374:81 - 84
   PubMed Web of Science ®Google Scholar
• Lundblad JR, Kwok RP, Laurance ME, Harter ML, Goodman RH. Adenoviral E1A-associated protein p300 as a functional homologue of the transcriptional co-activator CBP. Nature 1995; 374:85 - 88
   PubMed Web of Science ®Google Scholar
• Muraoka M, Konishi M, Kikuchi-Yanoshita R, Tanaka K, Shitara N, et al. p300 gene alterations in colorectal and gastric carcinomas. Oncogene 1996; 12:1565 - 1569
   PubMed Web of Science ®Google Scholar
• Gayther SA, Batley SJ, Linger L, Bannister A, Thorpe K, Chin SF, et al. Mutations truncating the EP300 acetylase in human cancers. Nat Genet 2000; 24:300 - 303
   PubMed Web of Science ®Google Scholar
• Suganuma T, Kawabata M, Ohshima T, Ikeda MA. Growth suppression of human carcinoma cells by reintroduction of the p300 coactivator. Proc Natl Acad Sci USA 2002; 99:13073 - 13078
   PubMed Web of Science ®Google Scholar
• Petrij F, Giles RH, Dauwerse HG, Saris JJ, Hennekam RC, Masuno M, et al. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 1995; 376:348 - 351
   PubMed Web of Science ®Google Scholar
• Miller RW, Rubinstein JH. Tumors in Rubinstein-Taybi syndrome. Am J Med Genet 1995; 56:112 - 115
   PubMed Web of Science ®Google Scholar
• Roelfsema JH, White SJ, Ariyurek Y, Bartholdi D, Niedrist D, Papadia F, et al. Genetic Heterogeneity in Rubinstein-Taybi Syndrome: Mutations in Both the CBP and EP300 Genes Cause Disease. Am J Hum Genet 2005; 76
   Google Scholar
• Eckner R, Ludlow JW, Lill NL, Oldread E, Arany Z, Modjtahedi N, et al. Association of p300 and CBP with simian virus 40 large T antigen. Mol Cell Biol 1996; 16:3454 - 3464
   PubMed Web of Science ®Google Scholar
• Patel D, Huang SM, Baglia LA, McCance DJ. The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J 1999; 18:5061 - 5072
   PubMed Web of Science ®Google Scholar
• Eckner R, Ewen ME, Newsome D, Gerdes M, DeCaprio JA, Lawrence JB, et al. Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor. Genes Dev 1994; 8:869 - 884
   PubMed Web of Science ®Google Scholar
• Goodman RH, Smolik S. CBP/p300 in cell growth, transformation and development. Genes Dev 2000; 14:1553 - 1577
   PubMed Web of Science ®Google Scholar
• Jeanmougin F, Wurtz JM, Le Douarin B, Chambon P, Losson R. The bromodomain revisited. Trends Biochem Sci 1997; 22:151 - 153
   PubMed Web of Science ®Google Scholar
• Marmorstein R, Berger SL. Structure and function of bromodomains in chromatin-regulating complexes. Gene 2001; 272:1 - 9
   PubMed Web of Science ®Google Scholar
• Kraus WL, Manning ET, Kadonaga JT. Biochemical analysis of distinct activation functions in p300 that enhance transcription initiation with chromatin templates. Mol Cell Biol 1999; 19:8123 - 8135
   PubMed Web of Science ®Google Scholar
• Syntichaki P, Topalidou I, Thireos G. The Gcn5 bromodomain co-ordinates nucleosome remodelling. Nature 2000; 404:414 - 417
   PubMed Web of Science ®Google Scholar
• Dhalluin C, Carlson JE, Zeng L, He C, Aggarwal AK, Zhou MM. Structure and ligand of a histone acetyltransferase bromodomain. Nature 1999; 399:491 - 496
   PubMed Web of Science ®Google Scholar
• Mujtaba S, He Y, Zeng L, Yan S, Plotnikova O, Sachchidanand, et al. Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation. Mol Cell 2004; 13:251 - 263
   PubMed Web of Science ®Google Scholar
• Mujtaba S, He Y, Zeng L, Farooq A, Carlson JE, Ott M, et al. Structural basis of lysine-acetylated HIV-1 Tat recognition by PCAF bromodomain. Mol Cell 2002; 9:575 - 586
   PubMed Web of Science ®Google Scholar
• Owen DJ, Ornaghi P, Yang JC, Lowe N, Evans PR, Ballario P, et al. The structural basis for the recognition of acetylated histone H4 by the bromodomain of histone acetyltransferase gcn5p. EMBO J 2000; 19:6141 - 6149
   PubMed Web of Science ®Google Scholar
• Jacobson RH, Ladurner AG, King DS, Tjian R. Structure and function of a human TAFII250 double bromodomain module. Science 2000; 288:1422 - 1425
   PubMed Web of Science ®Google Scholar
• St-Germain JR, Chen J, Li Q. Involvement of PML nuclear bodies in CBP degradation through the ubiquitin-proteasome pathway. Epigenetics 2008; 3:342 - 349
   PubMed Web of Science ®Google Scholar
• Chen J, Ghazawi FM, Bakkar W, Li Q. Valproic acid and butyrate induce apoptosis in human cancer cells through inhibition of gene expression of Akt/protein kinase B. Mol Cancer 2006; 5:71
   PubMed Web of Science ®Google Scholar
• Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002; 1:287 - 299
   PubMed Web of Science ®Google Scholar
• Marks PA, Jiang X. Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle 2005; 4:549 - 551
   PubMed Web of Science ®Google Scholar
• Riggs MG, Whittaker RG, Neumann JR, Ingram VM. n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 1977; 268:462 - 464
   PubMed Web of Science ®Google Scholar
• Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer and teratogen. J Biol Chem 2001; 276:36734 - 36741
   PubMed Web of Science ®Google Scholar
• Frew AJ, Johnstone RW, Bolden JE. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 2009; 280:125 - 133
   PubMed Web of Science ®Google Scholar
• Johannessen CU, Johannessen SI. Valproate: past, present and future. CNS Drug Rev 2003; 9:199 - 216
   PubMedGoogle Scholar
• Yoshida M, Horinouchi S, Beppu T. Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays 1995; 17:423 - 430
   PubMed Web of Science ®Google Scholar
• Chen J, Halappanavar SS, St-Germain JR, Tsang BK, Li Q. Role of Akt/protein kinase B in the activity of transcriptional coactivator p300. Cell Mol Life Sci 2004; 61:1675 - 1683
   PubMed Web of Science ®Google Scholar
• Avantaggiati ML, Carbone M, Graessmann A, Nakatani Y, Howard B, Levine AS. The SV40 large T antigen and adenovirus E1a oncoproteins interact with distinct isoforms of the transcriptional co-activator, p300. EMBO J 1996; 15:2236 - 2248
   PubMed Web of Science ®Google Scholar
• Yaciuk P, Moran E. Analysis with specific polyclonal antiserum indicates that the E1A-associated 300-kDa product is a stable nuclear phosphoprotein that undergoes cell cycle phase-specific modification. Mol Cell Biol 1991; 11:5389 - 5397
   PubMed Web of Science ®Google Scholar
• Smith JL, Freebern WJ, Collins I, De Siervi A, Montano I, Haggerty CM, et al. Kinetic profiles of p300 occupancy in vivo predict common features of promoter structure and coactivator recruitment. Proc Natl Acad Sci USA 2004; 101:11554 - 11559
   PubMed Web of Science ®Google Scholar
• Finzer P, Kuntzen C, Soto U, zur Hausen H, Rosl F. Inhibitors of histone deacetylase arrest cell cycle and induce apoptosis in cervical carcinoma cells circumventing human papillomavirus oncogene expression. Oncogene 2001; 20:4768 - 4776
   PubMed Web of Science ®Google Scholar
• Brownell JE, Allis CD. Special HATs for special occasions: linking histone acetylation to chromatin assembly and gene activation. Curr Opin Genet Dev 1996; 6:176 - 184
   PubMed Web of Science ®Google Scholar
• Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2003; 2:151 - 163
   PubMed Web of Science ®Google Scholar
• Takai N, Desmond JC, Kumagai T, Gui D, Said JW, Whittaker S, et al. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 2004; 10:1141 - 1149
   PubMed Web of Science ®Google Scholar
• Ohshima T, Suganuma T, Ikeda M. A novel mutation lacking the bromodomain of the transcriptional coactivator p300 in the SiHa cervical carcinoma cell line. Biochem Biophys Res Commun 2001; 281:569 - 575
   PubMed Web of Science ®Google Scholar
• Manning ET, Ikehara T, Ito T, Kadonaga JT, Kraus WL. p300 forms a stable, template-committed complex with chromatin: role for the bromodomain. Mol Cell Biol 2001; 21:3876 - 3887
   PubMed Web of Science ®Google Scholar
• Agalioti T, Chen G, Thanos D. Deciphering the transcriptional histone acetylation code for a human gene. Cell 2002; 111:381 - 392
   PubMed Web of Science ®Google Scholar
• Kraus WL, Kadonaga JT. p300 and estrogen receptor cooperatively activate transcription via differential enhancement of initiation and reinitiation. Genes Dev 1998; 12:331 - 342
   PubMed Web of Science ®Google Scholar
• Zeng L, Zhou MM. Bromodomain: an acetyl-lysine binding domain. FEBS Lett 2002; 513:124 - 128
   PubMed Web of Science ®Google Scholar
• Chen J, St-Germain JR, Li Q. B56 Regulatory Subunit of Protein Phosphatase 2A Mediates Valproic Acid-Induced p300 Degradation. Mol Cell Biol 2005; 25:525 - 532
   PubMed Web of Science ®Google Scholar
• Chen J, Halappanavar S, Th' ng JP, Li Q. Ubiquitin-dependent distribution of the transcriptional coactivator p300 in cytoplasmic inclusion bodies. Epigenetics 2007; 2:92 - 99
   PubMed Web of Science ®Google Scholar